We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+19.05%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.5B
AUM Growth
–
Cap. Flow
+$198M
Cap. Flow %
13.22%
Top 10 Hldgs %
43.16%
Holding
169
New
166
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$31.5M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$16.3M
3
ABBV icon
AbbVie
ABBV
+$15.6M
4
ZTS icon
Zoetis
ZTS
+$14.9M
5
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$12.2M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 10.7%
2 Energy 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NURO
151
DELISTED
NeuroMetrix, Inc. Common Stock
NURO
$357K 0.02%
+70
New +$371K
CRDC
152
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$354K 0.02%
+31,898
New +$401K
GYRE icon
153
CALL
Gyre Therapeutics
GYRE
$629M
$352K 0.02%
+1
New +$3.81K
LINE
154
PUT
DELISTED
LINN ENERGY LLC COM UTS REP LTD LIABILITY CO INTS
LINE
$332K 0.02%
+100
New +$3.56K
FRTX
155
PUT
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
0
– –
ALBO
156
PUT
DELISTED
Albireo Pharma Inc
ALBO
$322K 0.02%
+26
New +$2.71K
CDMO
157
CALL
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$320K 0.02%
+354
New +$3.71K
APEN
158
DELISTED
Apollo Endosurgery, Inc.
APEN
$312K 0.02%
+921
New +$346K
RMTI icon
159
PUT
Rockwell Medical
RMTI
$27.2M
$304K 0.02%
+8
New +$3.39K
QLTI
160
DELISTED
QLT Inc
QLTI
$295K 0.02%
+67,300
New +$543K
RXII
161
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$287K 0.02%
+1,291
New +$287K
FBIO icon
162
PUT
Fortress Biotech
FBIO
$111M
$283K 0.02%
+22
New +$3.24K
PTN
163
Palatin Technologies
PTN
$14.4M
$257K 0.02%
+342
New +$262K
OREX
164
PUT
DELISTED
Orexigen Therapeutics, Inc.
OREX
$255K 0.02%
+44
New +$2.71K
ARAY icon
165
Accuray
ARAY
$27.5M
$244K 0.02%
+42,491
New +$215K
IMNN icon
166
PUT
Imunon
IMNN
$6.47M
– –
0
– –
NSPR icon
167
InspireMD
NSPR
$31.4M
– –
0
– –
EXEL icon
168
CALL
Exelixis
EXEL
$13.9B
$217K 0.01%
+478
New +$2.27K
CERS icon
169
CALL
Cerus
CERS
$575M
$211K 0.01%
+477
New +$2.31K
3 4 5 6
7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AB
Aozora Bank Tokyo, Japan $43.6M AUM 1.15% 1-Year Est. Return

Sabby Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Sabby Management, which disclosed 169 positions worth $1.5B. Its ten largest holdings account for 43% of the portfolio.

Its largest position is Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, followed by Energy.

  • Sabby Management's largest Q2 2013 buy was Aegerion Pharmaceuticals: 593,862 shares worth $37.6M.
  • Sabby Management's ten largest holdings make up 43% of its $1.5B portfolio in Q2 2013.
  • Sabby Management disclosed 169 positions in Q2 2013, its first 13F filing on record.

Based on Sabby Management's 13F filing for Q2 2013, filed 14 Aug 2013.